Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A two-month, multi-center, randomized, double-blind, placebo-controlled hepatic safety study of ubrogepant in healthy volunteers

Trial Profile

A two-month, multi-center, randomized, double-blind, placebo-controlled hepatic safety study of ubrogepant in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2018

At a glance

  • Drugs Ubrogepant (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 25 Oct 2018 New trial record
    • 17 Oct 2018 According to an Allergan media release, based on the completion of this safety study and results from the ACHIEVE I (UBR-MD-01) and ACHIEVE II (UBR-MD-02) studies, the company will submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the first quarter of 2019.
    • 17 Oct 2018 According to an Allergan media release, this study was conducted based on FDA recommendations to complete a hepatic safety study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top